Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-171191
- Development stage
- Discontinued
- Lead developer
- Aligos Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALG-171191 is an antisense oligonucleotide (ASO) designed for the treatment of chronic hepatitis B virus (HBV) infection. Developed by Aligos Therapeutics in collaboration with Amoytop Biotech, ALG-171191 is designed to achieve a functional cure for HBV by utilizing a dual mechanism of action: RNase H-mediated direct antiviral activity (targeting HBV RNA to reduce HBsAg levels) and immunomodulatory activity via Toll-like receptor 8 (TLR8) agonism. In preclinical evaluations, ALG-171191 demonstrated enhanced in vitro RNase H-mediated activity and deeper HBsAg knockdown in mouse models compared to clinical-stage benchmarks like bepirovirsen. However, during lead optimization, sibling candidates ALG-170675 and ALG-171036 were selected as the optimal candidates for further development due to superior safety profiles in HBV-infected humanized liver mouse models.
02
Targets
TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on ALG-171191.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-171191.